The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine

Moustapha Hassan,1,2 Hatem Sallam,1 Zuzana Hassan1,2

*Corresponding Author email: moustapha.hassan@ki.se

Research Centrum, Karolinska University Hospital, Huddinge, Stockholm, Sweden.

ABSTRACT: Pharmacokinetics, pharmacodynamics and pharmacogenetics play an important role in drug discovery and contribute to treatment success. This is an essential issue in cancer treatment due to its high toxicity. During the last decade, cyclin-dependent kinase inhibitors were recognised as a new class of compounds that was introduced for the treatment of several diseases including cancer. Cyclin-dependent kinases (Cdks) play a key role in the regulation of cell cycle progression and ribonucleic acid transcription. Deregulation of Cdks has been associated with several malignancies, neurodegenerative disorders, viral and protozoa infections, glomerulonephritis and inflammatory diseases. (R)-roscovitine is a synthetic tri-substituted purine that inhibits selectively Cdks 1, 2, 5, 7 and 9. Roscovitine has shown promising cytotoxicity in cell lines and tumor xenografts. In this paper, we present several aspects of pharmacokinetics (PK) and pharmacodynamics (PD) of roscovitine. We present also some of our investigations including bioanalysis, haematotoxicity, age dependent kinetics, PK and ADME. During the last decade, cyclin-dependent kinase inhibitors were recognised as a new class of compounds that was introduced for the treatment of several diseases including cancer. Cyclin-dependent kinases (Cdks) play a key role in the regulation of cell cycle progression and ribonucleic acid transcription. Deregulation of Cdks has been associated with several malignancies, neurodegenerative disorders, viral and protozoa infections, glomerulonephritis and inflammatory diseases. (R)-roscovitine is a synthetic tri-substituted purine that inhibits selectively Cdks 1, 2, 5, 7 and 9. Roscovitine has shown promising cytotoxicity in cell lines and tumor xenografts. In this paper, we present several aspects of pharmacokinetics (PK) and pharmacodynamics (PD) of roscovitine.

1Experimental Cancer Medicine (ECM), Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; 2Clinical Research Center, Karolinska University Hospital, Huddinge, Stockholm, Sweden.

*Corresponding Author email: moustapha.hassan@ki.se

ACKNOWLEDGEMENTS

This work was supported by grants from Cancer Research UK (grant numbers C9193/A10251 and C4452/A16171). The authors thank the Medical Research Council for support.

REFERENCES

Clinical approval of new drugs is preceded by intensive research consisting of two steps, drug discovery and drug development. In the drug discovery stage, target enzymes and/or receptors for a particular disease are identified, and new molecules are designed and screened for their biological activities. Promising drug candidates are evaluated for their toxicity and efficacy in the development stage.1

Studies on the metabolism and pharmacokinetics (DMPK) of candidate drugs have become an essential part in drug discovery and development programmes and start usually concomitantly with the screening for biological activity. It is estimated that approximately 10–40% of drug candidates fail due improper pharmacokinetic properties. Further, DMPK studies provide vital information about the PK/PD (pharmacokinetics/pharmacodynamics) relationship.2 This knowledge is prerequisite for safety phase I clinical trials3 and prediction of a clinical effective dose. Moreover, PK is essential for further investigation of drugs in phase II and III clinical trials. PK/PD also play important roles in dose optimisation, personalised treatment and prevention of side effects. This in turn determines the clinical outcome. These aspects are especially important in anticancer drugs due to their toxicities and the narrow therapeutic window.

Age is one of the important factors affecting the PK and efficacy of drugs. Variability in drug exposure and efficacy occurs among the different age populations, i.e. children, adults and elderly. It is essential to investigate the PK parameters in the age population that is treated with the drug. In the younger aged population, doses of many drugs are still not optimised due to lack of knowledge about drug disposition and PK in this particular population. Several factors such as the ontogeny of the metabolising enzymes and drug transporters are responsible for the variability of DMPK.4 Continuous efforts are being made to develop accurate PK models to predict the PK parameters in this population without conducting a large scale investigation which might be difficult due to technical and ethical restraints.5 Age-dependent pharmacokinetics in young animals at different stages of development should be considered before clinical use.6

Cyclin-Dependent Kinases

Cyclin-dependent kinases (Cdks) are a family of serine/threonine kinases that are activated through binding to regulatory subunits called cyclins.7 Cdk enzymes are homologues and highly conserved in their cyclin binding domain. Despite the fact that the human sequencing programme has successfully indentified 20 Cdks and 25 cyclins, their functions are still not fully understood and a limited number of active Cdk/cyclin complexes have been identified so far.7

Cyclin-dependent kinases are regulated by several mechanisms2 including, transcription and translation of their subunits, heterodimerisation with cyclins, post-translational modification by phosphorylation and dephosphorylation and interactions with the natural inhibitors. The natural inhibitors CIP/KIP (p21, p27, p57) suppress the Cdk/cyclin complexes and INK4 proteins (p15, p16, p18 and p19) inhibit the Cdk4 and Cdk6 monomers. Cdk/cyclin complexes play an essential role in the regulation of the cell cycle progression. Cyclins transcription and degradation varies during the different phases of the cell cycle and lead to the activation or inactivation of the corresponding Cdks.

During the last decade, the roles of Cdks in several diseases including cancer were extensively studied. Over expression of cyclin B1 and hyperactivation of Cdk1 has been observed in a number of primary tumours including breast-, colon- and prostate carcinoma. Inactivation of Cip–Kip inhibitors and over expression of cyclin E and/or cyclin A lead to deregulation of Cdk2 in various malignancies, including melanoma, ovarian...
with adenosine triphosphate (ATP) for binding in the kinase ATP-binding site, and 4) Cdks bind mostly by hydrophobic interactions and hydrogen bonds with the kinase.

Cdks have been classified according to their selectivity into three groups: 1) Pan-Cdks that inhibit Cdk1, 2, 4, 5, 6, 7 and 9 with almost similar potency like flavopiridol; 2) Selective Cdks for Cdk5 1, 2, 5, 7 and 9 such as the 2, 6, 9 tri-substituted purines (olomoucine, roscovitine and purvalanol), and 3) Selective Cdks for Cdk4 and 6 (PD-0332991 or P-276–00).

(R)-Roscovitine (CYC202)

Roscovitine belongs to the 2, 6, 9 tri-substituted purines [Figure 1]. Roscovitine was found to be a selective inhibitor for Cdk1, 2, 5, 7 and 9. In the kinase inhibitory assay, roscovitine has been shown to inhibit these kinases with the IC50 at the nanomolar range. Roscovitine was also found to inhibit several other kinases such as CaM Kinase 2, CK1α, CK1δ, DYRK1A, EPHB2, ERK1, ERK2, FAK, and IRAK4 at the micromolar range (1-40 µM). However, other kinases including Cdk4, Cdk6 and Cdk8 were not sensitive to roscovitine.

Since Cdks have an important role in a wide range of cellular functions, roscovitine has been suggested as a potential treatment for several pathophysiologically different diseases. The effects of roscovitine have been studied in vitro in cell lines and in vivo in animal models. The in vitro effects of roscovitine have been studied in more than 100 cell lines. Several studies have reported the IC50 required to inhibit cell proliferation including the NCI 60 cell line panel (average IC50 = 16 µM), McClue et al. panel (19 cell lines; average IC50 = 15.2 µM), and Raynaud et al. panel (24 cell lines; average IC50 = 14.6 µM). The IC50 average required for inhibition of cell proliferation in cancer cell lines does not exceed 17 µM; moreover, roscovitine was shown to be cell cycle phase nonspecific. Direct inhibition of several Cdks results in inhibition of the exit from G0 (Cdk3/cyclin C), G1/S transition (Cdk2/cyclin E), S phase progression (Cdk2/ cyclin A), G2 phase (Cdk1/Cyclin A) and G2/M transition (Cdk1/Cyclin B). Depending on the cycling status of the cells, the antimitotic effects of roscovitine may comprise combinations of these mechanisms.

carcinoma, lung carcinoma and osteosarcoma. Cdk5 has been found to modulate the metastatic potential of some malignancies including breast and prostate carcinomas.

Cdk2 and Cdk5 have been shown to play important roles in apoptosis in various tissues. Cdk2 was found to regulate apoptosis in thymocytes, while subcellular localisation of Cdk2 have been found as a determinant of the apoptotic or proliferative fate of mesangial cells.

Cdk5 has an essential role in the central and peripheral nervous system. Cdk5 regulates the cytoarchitecture of the developing brain and mediates the neuronal migration in the post mitotic neurons. Cdk5 has also many important functions in the neuronal cytoskeleton dynamics, synaptic plasticity, drug addiction, synaptic endocytosis and neurotransmitter release. Cdk5 may be involved in the pathogenesis of several neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. It has been shown that Cdk9 induces the differentiation in distinct tissues and the degree of expression of Cdk9 correlates with differentiation of primary neuroectodermal and neuroblastoma tumours.

Due to the important role of Cdks in several diseases including cancer, intensive efforts to find selective cyclin-dependent kinase inhibitors (Cdki) have been made during the last 15 years. Several classes of different Cdki have been identified. In spite of their chemical diversity they share common characteristics: 1) Cdkis have low molecular weights (about 600); 2) Cdkis are flat hydrophobic heterocyclic compounds; 3) Cdkis act by competing
Indirect inhibition of the cell cycle by roscovitine is mediated through the inhibition of the activity of Cdk7/ cyclin H/ MAT1 (CAK) resulting in prevention of the phosphorylation of the T loop threonine of various Cdks. This finally decreases the activity of Cdk1, 2 and 4. Also phosphorylation of the natural inhibitor p27 by Cdk2 will be diminished leading to its stabilisation and more inhibition of the cell cycle. In addition, roscovitine was shown to inhibit the initiation of DNA synthesis, the formation of centrosomes and the formation of the nucleolus.

Roscovitine has been shown to induce apoptosis in several cell lines regardless of the p53 status; however, roscovitine has a higher potency to induce apoptosis in wild type p53 cells compared to p53 null cells. Cell death has been detected in all phases of the cell cycle and different mechanisms may be involved including inhibition of the cell cycle due to p53 activation and inhibition of Cdk7/Cdk9-dependent transcription inhibiting RNA polymerase II enzyme.

Effects of roscovitine on global transcription have been shown to be limited and only few proteins such as Mcl-1, XIAP, and survivin have been found to be severely reduced. Induction of cell death by roscovitine, thus, seems to correlate rather well with inhibition of transcription of essential cell survival factors.

Down regulation of survivin and XIAP by roscovitine was shown to contribute to the activation of caspases in glioma cell. Alvi et al. have reported that roscovitine induced apoptotic cell death in chronic lymphocytic leukaemia B-lymphocytes at significantly higher level than in normal blood mononuclear cells, purified B- or T-lymphocytes. Apoptosis was caspase-dependent but p53-independent and was accompanied with down regulation of Mcl-1 and XIA.

Anti-proliferative and pro-apoptotic effects of roscovitine have been implicated in cancer treatment and used in studies on the antitumour effects of roscovitine. So far, no cell line resistant to roscovitine has been reported until now.

Interestingly, tumour cells are more dependent on the short-lived survival factors compared to normal cells, and thus, down regulation of these factors by roscovitine treatment has a higher impact on tumour cells. Synergistic effects of roscovitine in combination with other chemotherapeutic agents such as camptothecin in MCF-7 breast tumour, irinotecan in p53-mutated colon cancer, histone deacetylase (LAQ824) in HL60 and Jurkat leukaemic cells and doxorubicin in sarcoma cell lines have been shown in vitro.

Antitumour effects of roscovitine as a single treatment, or in combination with conventional cytostatics, have been studied in vivo in various tumour xenografts models. Nude mice bearing human colorectal cancer or human uterine cancer xenografts were treated with roscovitine at different dosing schedules. Roscovitine inhibited the tumour growth rate and reduced tumour volumes and weights. Roscovitine was also shown to be effective in reducing the growth of A4573 (Ewing’s sarcoma) and PC3 prostate tumour xenografts.

The efficacy of roscovitine in non-nude BDF1 male mice bearing Glasgow osteosarcoma xenografts was investigated in relation to biological circadian rhythm. Roscovitine was administered orally (300 mg/kg x1 daily) for 5 days Zeitgeber time 3 (ZT3, 3 hours after light onset) or at ZT11 or ZT19. Roscovitine reduced the tumour growth by 35% when administered in the active time of the mice (ZT19) and 55% when administered during their rest span (ZT3 or ZT11).

Roscovitine showed higher antitumour activity when combined with other antitumour treatments. Maggiorella et al. have reported better reduction in tumour volume from 54% to 72% when a single dose of 100 mg/kg was given intraperitoneal (i.p.) and combined with radiation therapy in mice bearing MDA-MB 231 (breast cancer). Roscovitine was shown to have a synergistic effect in inhibiting HT29 colon cancer xenografts when combined with irinotecan.

Pharmacokinetics and Metabolism of Roscovitine

The PK of roscovitine have been reported in mice, rats and human. Vita et al. reported the PK and biodistribution of roscovitine in rats after a dose of 25 mg/kg. Roscovitine PK was described by a two-compartment open model and short elimination half-life (<30 min). The highest distribution of roscovitine was observed in lungs followed by liver, fat and kidney, while exposure to roscovitine in brain was 30% of that observed in plasma. Three major metabolites were detected in plasma, but no metabolites were detected in brain.
PK/PD of Roscovitine in the Bone Marrow in Mice

Myelosuppression is one of the most frequent complications and a dose limiting factor for the majority of conventional chemotherapeutic agents. Depending on the dose, several cytostatics may induce complete myeloablation of the bone marrow. Studies on haematotoxicity in vitro and in animal models help to predict the possible side effects prior to clinical trials.

In order to investigate the myelosuppressive potential of roscovitine we studied the effect of roscovitine on bone marrow cells in vitro and in vivo in Balb/c mouse. Crude bone marrow was incubated in vitro with roscovitine at concentrations of 25–250 µM for 4 hrs and viability was studied using resazurin assay. The viability of bone marrow cells was decreased in a concentration-dependent manner. Concentration of 250 µM significantly reduced the viability of the cells to 70% compared to controls ($P = 0.015$) while lower concentrations did not have a significant effect. Our results were in agreement with the findings that roscovitine induced apoptosis of mature neutrophils, eosinophils and proliferating T-cells in a concentration and exposure-time dependent manner. The myelosuppressive effect of roscovitine on haematopoietic progenitors was studied using a clonogeneic assay. Bone marrow cells were exposed to roscovitine at different concentrations (25–100 µM) for up to 24 hrs in suspension cultures. After washing, the capacity of haematopoietic progenitors to form colony-forming unit granulocyte/macrophage (CFU-GM), burst-forming unit erythroid (BFU-E) and colony-forming unit granulocyte/erythrocyte/macrophage/megakaryocyte (CFU-GEMM) colonies was studied using semisolid media. The clonogenic capacity of the bone marrow decreased in a concentration- and time-dependent manner. BFU-E colonies were more sensitive than CFU-GM and completely blocked after 12 and 24 hr incubation with both 50 and 100 µM of roscovitine. Since a decrease in the colony formation in controls after 12 and 24 hrs was observed, which most probably is due to lack of the growth factors in the suspension media, bone marrow cells were exposed to roscovitine (1 - 100 µM) in semisolid MethoCult media containing growth factors. Suppression of
colony formation in a concentration- and cell type-dependent manner was observed. CFU-GEMM were most sensitive and were completely blocked at 25 µM concentration, followed by BFU-E which were also significantly inhibited at 25 µM while CFU-GM were least sensitive and were inhibited at 100 µM only [Figure 2].

We further studied the myelosuppressive effect of roscovitine *in vivo* in female Balb/c mice. Roscovitine was administered to the mice and bone marrow cells were cultured in the MethoCult media and assessed for colonogenic growth. No myelosuppressive effect was detected after the administration of a single dose of roscovitine up to 250 mg/kg. Then, roscovitine was administered at a dose of 175 mg/kg twice daily for 4 days. Only transient inhibition of the BFU-E colonies occurred one day after the last dose of roscovitine. The colony formation capacity of bone marrow was recovered 5 days after the last dose of roscovitine [Figure 3]. The lack of activity of roscovitine on haematopoietic progenitors *in vivo* was not expected after its proven inhibitory effect *in vitro* and the reported activity on different xenografts *in vivo*.26,44,46,47 Therefore we decided to study the distribution and PK of roscovitine in Balb/c mice. Roscovitine was administered as a single i.p. injection in a dose of 50 mg/kg. As presented in Table 1, roscovitine had a short half-life (less than 1 hr) and only a small fraction of roscovitine (about 1.5%) reached the bone marrow compared to plasma. Thus, low distribution of roscovitine to bone marrow may explain the low haematotoxicity *in vivo*. This example illustrates the importance of PK/PD and biodistribution in preclinical studies. This may be also implicated in the fact that, despite a good cytotoxic effect of roscovitine in leukaemic cell lines in vitro, the therapeutic potential of roscovitine in haematological malignancies may be limited.

### Age-Dependent Kinetics and Dynamics of Roscovitine in Rat Brains

Age-dependent PK is an important issue when the drug may be used in the treatment of paediatric patients and/or when the drug has a narrow therapeutic window. Unfortunately, scaling down the PK data from adults to paediatrics, has been proven not to be sufficiently predictive for many drugs.4 Roscovitine has been found to inhibit different solid and haematological tumour cell lines including acute lymphoblastic leukaemia (ALL)45 which is frequent in children and is correlated with a high central nervous system (CNS) relapse rate.62

Recently, we have explored the effect of age on the PK of roscovitine and investigated the effect of roscovitine on two neuronal targets, Cdk5 and Erk1/2, in different brain regions.63 Fourteen day-old pups and adult Sprague-Dawley rats were
Moustapha Hassan, Hatem Sallam and Zuzana Hassan

**Table 1:** Pharmacokinetic parameters in plasma and bone marrow following intraperitoneal administration of roscovitine (50 mg/kg)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Plasma</th>
<th>BM</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC µmol/l.h</td>
<td>275.8</td>
<td>4.6</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; µmol/l</td>
<td>202</td>
<td>4.9</td>
</tr>
<tr>
<td>Cl l/h</td>
<td>0.05</td>
<td>0.62</td>
</tr>
<tr>
<td>V&lt;sub&gt;d&lt;/sub&gt; l</td>
<td>0.015</td>
<td>0.54</td>
</tr>
<tr>
<td>T½ h</td>
<td>0.82</td>
<td>0.61</td>
</tr>
</tbody>
</table>

Legend: AUC = area under the concentration–time curve (AUC is derived using WinNonlin analysis); C<sub>max</sub> = estimated maximum concentrations; Cl = clearance; V<sub>d</sub> = apparent volume of distribution; T½ = half-life; BM = Bone marrow.

The area under the concentration–time curve (AUC) of roscovitine was 22-fold higher in the pups’ plasma and 100-fold higher in the pups’ brains compared to that found in adult rats [Figure 4]. No significant difference between roscovitine AUC in plasma and AUCs in different brain regions in pups was found. On the contrary, in adult rats, the AUC of roscovitine in the brain was about 25% of that found in plasma (Table 2). The C<sub>max</sub> was significantly (P<0.05) higher (>22 µg/g) in pups brain compared to that found in plasma, while 4-fold higher C<sub>max</sub> was found in plasma compared to that observed the brain (17.7 µg/ml and about 4 µg/g, respectively) in adult rats. The high concentrations of roscovitine found in the pups’ brains indicate the free passage of roscovitine into the brain.

This difference in exposure might be due to the immaturity of the CYP450 enzymes responsible for roscovitine metabolism or immaturity of BBB. Roscovitine is metabolised in humans mainly by CYP3A4 and CYP2B6 enzymes. Several CYP450 enzymes are not fully matured at the age of 2 weeks in rats. A similar situation was also reported in humans and CYP3A4, for example, approaches the adult full capacity only after first year of life.

Most chemotherapeutic agents do not cross the BBB and do not reach the CNS in enough high concentrations to eliminate tumour cells despite
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine

Butt et al. have shown that the BBB of the rat fully matures 3–4 weeks postnatal. No roscovitine metabolites were found in the brains of both adult and young rats. In pups, roscovitine concentrations in plasma and brain were higher than the reported IC50 (10-15 µM) for cancer cell lines for more than 8 hours. However, this level of exposure was achieved for less than the high systemic exposure. Roscovitine was highly distributed over the BBB in the pups and the brain exposure in all studied regions (e.g. hippocampus, cerebral cortex and cerebellum) was 100% of that found in plasma which can be compared to about 25% that has been found in the brain of adult rats. The high distribution to the brain could be explained by an age-dependent variation in the maturity and function of BBB. Butt et al. have shown that the BBB of the rat fully matures 3–4 weeks postnatal.

No roscovitine metabolites were found in the brains of both adult and young rats.

In pups, roscovitine concentrations in plasma and brain were higher than the reported IC50 (10-15 µM) for cancer cell lines for more than 8 hours. However, this level of exposure was achieved for less than the high systemic exposure.

### Table 2: Pharmacokinetic parameters in plasma and brain of adult and pups rats. Results are presented as mean ± standard deviation (SD) (n = 3)

<table>
<thead>
<tr>
<th>PK parameters</th>
<th>Plasma</th>
<th>Frontal Cortex</th>
<th>Hippocampus</th>
<th>Cerebellum</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC (h.μg/ml)/ (h.μg/g)</td>
<td>Pups</td>
<td>66.79 ± 7.15</td>
<td>69.57 ± 15</td>
<td>74.92 ± 12</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>3.01 ± 0.21</td>
<td>0.71 ± 0.14</td>
<td>0.58 ± 0.03</td>
</tr>
<tr>
<td>Tα (h)</td>
<td>Pups</td>
<td>0.50 ± 0.09</td>
<td>0.48 ± 0.19</td>
<td>0.43 ± 0.1</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>0.081 ± 0.05</td>
<td>0.045 ± 0.02</td>
<td>0.062 ± 0.012</td>
</tr>
<tr>
<td>Tβ (h)</td>
<td>Pups</td>
<td>7.2 ± 1.4</td>
<td>6.8 ± 1.3</td>
<td>8.0 ± 1.7</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>0.54 ± 0.26</td>
<td>0.35 ± 0.13</td>
<td>0.36 ± 0.15</td>
</tr>
<tr>
<td>Cmax (μg/ml)/ (μg/g)</td>
<td>Pups</td>
<td>15.79 ± 0.38</td>
<td>24.9 ± 1.8</td>
<td>24.75 ± 1.9</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>17.71 ± 4.42</td>
<td>4.47 ± 0.70</td>
<td>4.64 ± 0.81</td>
</tr>
<tr>
<td>Vss (ml)</td>
<td>Pups</td>
<td>88 ± 15.3</td>
<td>90 ± 21</td>
<td>86 ± 20</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>650 ± 223</td>
<td>1095 ± 167</td>
<td>2056 ± 219</td>
</tr>
<tr>
<td>Cl (ml/h)</td>
<td>Pups</td>
<td>9.7 ± 1.2</td>
<td>10.2 ± 1.5</td>
<td>11.1 ± 2</td>
</tr>
<tr>
<td></td>
<td>Adults</td>
<td>1637 ± 118</td>
<td>7262 ± 1612</td>
<td>8737 ± 452</td>
</tr>
</tbody>
</table>

Legend: AUC = Area under the concentration–time curve; Tα, Tβ = distribution and elimination half-lives; Cmax = maximum concentration; Vss = volume of distribution; Cl = clearance.

Figure 5: Effect of roscovitine on cyclin-dependent kinase 5 – neuronal protein specific cyclin-dependent kinase (Cdk) Cdk5 regulator (Cdk5-p35) in different brain parts of 14 days old rat pups after single intraperitoneal (i.p.) injection of 25 mg/kg. Pups were killed at different time points after injection, brains dissected, homogenised, and immunoblotted for active Cdk5-p35. The figure shows densitometric analysis of the Western blotting bands for both p35 in the frontal cortex, hippocampus and cerebellum until 48 hr after single i.p. injection of roscovitine. Data are presented as mean ± standard deviation (SD) of values expressed as percentage of control animals (*, P < 0.05 for analysis of p35 data; Analysis of variance (ANOVA) followed by all pairwise Fisher’s Protected Least Significant Difference (PLSD) testing were used.)
than 30 minutes in plasma and brain of adult rats. These results may be implicated in the treatment of paediatric malignancies especially brain tumours.

Roscovitine is a potent inhibitor of Cdk5 which has important function in the developing brain such as neuronal migration. Moreover, the negative feedback regulation of mitogen activated protein kinases (MAPK) signalling by Cdk5 has been suggested to be important for neuronal survival.

High concentrations of roscovitine found in the brain of pups raised the question about the effects of roscovitine on target enzymes. We assessed the expression of p35 as an indicator of Cdk5 activity. Inhibition of p35 phosphorylation by Cdk5 stabilises it and delays its proteasomal degradation. Roscovitine induced a transient and significant accumulation of p35 protein in all brain regions in rat pups that indicates the inhibition of the Cdk5 enzyme. An increase in p35 was found in the frontal cortex 1–2 hrs post-administration (140% of controls, Figure 5, \( P < 0.05 \)), in the hippocampus and in cerebellum at 2 hrs post-administration (150% and 200%, respectively, Figure 5). The levels of p35 were normalised at 6–15 h [Figure 5]. No change in p35 levels was observed in the adult brain which probably is due to the low concentration and the rapid elimination half-life.

Cdk5 was found to inhibit Erk1/2 phosphorylation by a MEK1 and RasGRF2 mediated mechanism and the inhibition of Cdk5 by roscovitine increased the levels of phosphorylated Erk1/2 (active form) in neuronal cells in vitro. At early time points after administration of roscovitine, the accumulation of p35 protein was accompanied by increased levels of the phosphorylated (activated) form of Erk1/2. In the frontal cortex and hippocampus, a transient activation of Erk1/2 was observed at 1 and 2 hrs after injection [Figure 6]. In the cerebellum, significant increases of pErk1/2 levels at 2 hrs were followed by a significant decrease at 6 hrs after administration [Figure 6]. At later time points, levels of pErk1/2 returned to control levels in all brain regions [Figure 6]. Altogether, roscovitine was presented in the brain of rat pups in sufficient amounts to inhibit the Cdk5 resulting in increased phosphorylation of Erk1/2.

**Discussion**

Cyclin-dependent kinases (Cdks) are serine/threonine kinases that play key roles in cell cycle progression and RNA transcription. Deregulation of Cdks has been shown in several diseases including several types of cancer in which increased activity of Cdks has been observed. Synthetic cyclin dependent kinase inhibitors (Cdks) are small heterocyclic compounds which compete

Figure 6: Effect of roscovitine on p-Erk in different brain parts of rat pups 14 days old after single intraperitoneal (i.p.) injection of 25 mg/kg. Pups were killed at different time points after injection, brains dissected, homogenized, and immunoblotted for active phosphorylated Erk1/2. Control animals were injected with vehicle. The figure show densitometric analysis of the Western blotting bands for pErk1/2 in the frontal cortex, hippocampus and cerebellum until 48 hr after single i.p. injection of roscovitine. Data are presented as mean ± standard deviation (SD) of values expressed as percentage of control animals (*, \( P < 0.05 \) is the significant level for analysis of p-ERK data; Analysis of variance (ANOVA) followed by all pairwise Fisher’s Protected Least Significant Difference (PLSD) post-hoc test).
The Role of Pharmacokinetics and Pharmacodynamics in Early Drug Development with reference to the Cyclin-dependent Kinase (Cdk) Inhibitor - Roscovitine

with ATP and inhibit the phosphorylation of the target substrates. Exposure of tumour cells to Cdkis results in both cell cycle arrest and apoptosis.

The family of 2,6,9-trisubstituted purines are one of the first described Cdk inhibitors. The (R)-stereoisomer of roscovitine is a member of this family and has now reached phase II clinical trials for non-small cell lung (NSCL) cancer and nasopharyngeal cancers and phase I trials for glomerulonephritis. Preclinical investigations of the role of roscovitine in the treatment of neurodegenerative disorders such as Alzheimer's disease, viral infections, protozoal infections and inflammatory diseases are ongoing. Roscovitine has a rapid metabolism and short elimination half-life in rodents and man. The poor pharmacokinetic profile and the insufficient exposure to the drug in cancer patients may explain the modest success in the clinical trials. Current research is focusing on overcoming pharmacokinetic barriers that limit the clinical use of roscovitine. Moreover, a novel class of second generation analogues of roscovitine has been designed and is under development. Studies on the pan-Cdk inhibitor flavopiridol confirmed the importance of optimising the schedule of dosing according to the PK/PD relationship. By changing the dose schedule from 72 hrs infusion to 30 minutes i.v. bolus followed by a 4-hrs infusion, a significant difference in the clinical outcome and final response of refractory CLL patients was achieved.

No myelosuppression has been reported until now in the preclinical and clinical studies with roscovitine. However, clinically beneficial low haematotoxicity of roscovitine may reflect in reality poor distribution of roscovitine to the bone marrow. In vitro, the haematopoietic progenitors were inhibited by roscovitine within the same exposure range as the tumour cells when comparing the inhibitory AUC reported for tumour cell lines with the inhibitory AUC of the haematopoietic progenitors found in our study.

Under certain circumstances the haematotoxicity of roscovitine may become more evident: 1) Changes in the form of administration, aiming to increase the half-life of the drug, may result in higher exposure to roscovitine and changes in biodistribution. This in turn may change the toxicity profile; 2) A combination of roscovitine with radiation therapy, which increases the permeability of blood-bone marrow barrier, and thus the distribution of some drugs to the bone marrow, may increase the myelotoxicity of roscovitine, and 3) In pediatric patients where age-dependent longer elimination half-life is most likely leading to higher exposure of haematopoietic progenitors to roscovitine and thus toxicity risk.

Figure 6: Effect of roscovitine on p-Erk in different brain parts of rat pups 14 days old after single intraperitoneal (i.p.) injection of 25 mg/kg. Pups were killed at different time points after injection, brains dissected, homogenized, and immunoblotted for active phosphorylated Erk1/2. Control animals were injected with vehicle. The figure show densitometric analysis of the Western blotting bands for pErk1/2 in the frontal cortex, hippocampus and cerebellum until 48 hr after single i.p. injection of roscovitine. Data are presented as mean ± standard deviation (SD) of values expressed as percentage of control animals (*, P < 0.05 is the significant level for analysis of p-ERK data; Analysis of variance (ANOVA) followed by all pairwise Fisher’s Protected Least Significant Difference (PLSD) post-hoc test).
Age dependent PK is an important issue concerning toxic drugs and drugs with a narrow therapeutic window such as anticancer drugs, where underdosing may lead to relapse while overdosing can cause severe side effects. Age dependent kinetics were reported for several drugs including cis platim, busulfan, thioguanine, etoposide, lamivudine and mycophenolate mofetil.76-81 Our studies showed that roscovitine elimination half-life was 14-fold higher in young rats compared to adults. Moreover, the exposure to the drug was 22-fold and 100-fold higher in the plasma and brain, respectively. These results indicate the importance of early determination of the PK-parameters in different age groups.

Conclusion

Roscovitine inhibits mouse haematopoietic progenitors in vitro within the same concentration range required to inhibit malignant cells; however, the cytotoxic effect of roscovitine on haematopoietic progenitors in vivo is transient due to a short half-life in combination with low distribution to the arrow compartment. Roscovitine demonstrates age-dependent PK. Prolonged systemic and brain exposure to roscovitine was found in pups compared to adult rats, which may be due to immature CYP450 enzymes as well as the BBB. Moreover, roscovitine was able to induce a transient effect on critical neuronal targets and signalling pathways in the brain of young rats. These studies show the importance of early pharmacokinetic and phamacodynamic studies in drug development.

ACKNOWLEDGMENTS

The authors would like to express their gratitude to the Swedish Cancer Foundation (Cancer Fonden) and the Swedish Children Cancer Society (Barn Cancer Fonden) for their support for this work.

References


57. McClue SJ, Stuart I. Metabolism of the trisubstituted purine cyclin-dependent kinase inhibitor seliciclib (r-roscovitine) in vitro and in vivo. Drug Metab Dispos 2008; 36:561–70.


71. Patrick GN, Zhou P, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the...


